Patients with advanced multiple myeloma have a new treatment option with the FDA’s approval of a GlaxoSmithKline drug that targets B-cell maturation antigen, a protein found on the surface of cancerous plasma cells.
The agency OK’d the London-based pharma giant’s cancer drug, belantamab mafodotin (Blenrep), based on the results of a study in which patients with the blood cancer received the drug intravenously every three weeks until their disease progressed or the side effects became too much to handle.
Patients that received the GSK (NYSE: GSK) drug in the trial, dubbed DREAMM-2, had previously undergone a median of seven prior… Read more »
UNDERWRITERS AND PARTNERS
